Aspirin vs. Indomethacin in the Treatment of Patent Ductus Arteriosus in Very Low Birth Weight Infants.
- Author:
Young Ah LEE
1
Author Information
1. Department of pediatrics, College of Medicine, Dong-A University, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
Very low birth weight infant;
Patent ductus arteriosus;
Aspirin
- MeSH:
Aspirin*;
Birth Weight;
Ductus Arteriosus, Patent*;
Gestational Age;
Humans;
Indomethacin*;
Infant*;
Infant, Very Low Birth Weight*;
Medical Records
- From:Journal of the Korean Society of Neonatology
2001;8(2):257-264
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the effect of indomethacin to aspirin in the closure of patent ductus arteriosus (PDA) in very low birth weight (VLBW) infants with respiratory distress syndrome. To evaluates the side effects of aspirin in very low birth weight infants. METHODS: We evaluated 25 VLBW infants treated with either indomethacin or aspirin for PDA as shown by their medical recorder. In 12 infants (mean gestational age 30.3+/-2.1 wk, mean birth weight 1232.0+/-314.3 gm) were treated with indomethacin, 0.1-0.25 mg per kilogram, every 12 hours for 3 doses. In another 13 infants (mean gestational age: 29.1+/-2.1 wk, mean birth weight: 1180.0+/-332.4 gm) aspirin was administered 10 mg per kilogram, every six hours for four doses. PDA and the degree of shunting were evaluated by echocardio-Doppler. The side effects were carefully assessed. RESULTS: There was PDA closure in 8/12 patients from the indomethacin group (66.7%) and in 9/13 patients from the aspirin group (69.2%). Six patients were further treated with indomethacin there was and PDA closure. A decrease of uresis in the aspirin group was not observed. Conclusions : Aspirin has some effect in the closure of PDA in VLBW infants without a decrease of renal function.
